Real-World Evidence Shows Paliperidone Long-Acting Injectable Further Reduces Relapse Risk and Hospitalization Duration

 

                       

EM-173909 Approved date 2024-12-23

This material is owned by Johnson & Johnson Innovative Pharmaceuticals, intended for reference by medical and pharmaceutical professionals only. Without approval, reprinting, reproduction, or dissemination is strictly prohibited.

This material is intended for medical and scientific exchange only and may involve products and indications not yet approved in China. Johnson & Johnson Innovative Pharmaceuticals does not support or encourage the use of any unapproved drugs/indications.

The AE/SS/PQC involved in this material have been reported in accordance with the company's requirements.